Raul Gainetdinov Explained

Birth Name:	Raul R. Gainetdinov
Birth Date:	1964 9, mf=yes
Workplaces:	Duke University Italian Institute of Technology Saint Petersburg University
Known For:	TAAR Dopamine receptors
Field:	Neuropsychopharmacology Medicine Biology

Raul Gainetdinov (born September 1, 1964) is a pharmacologist and neuroscientist. The main direction of his research is psychiatric and neurological diseases of the brain, such as schizophrenia, ADHD, depression and Parkinson's disease. He is the author of fundamental scientific works in pharmacology of dopamine,^[1] β-Arrestins^{[2] [3]} and NMDA receptors.^[4] He is a pioneer researcher of Trace amine-associated receptors.^{[5] [6] [7]}

Education

He earned an MD degree from the Second Moscow Medical Institute (now the Russian National Research Medical University) in 1988, followed by a PhD degree in Pharmacology in 1992 from the Russian Academy of Medical Sciences.^[8]

Career

• 1988-1996 PhD student - Senior Scientist, Institute of Pharmacology, Russian Academy of Medical Sciences, Moscow, Russia.^[9]
• 1996-2008 Postdoctoral Researcher - Associate Research Professor, Department of Cell Biology, Duke University, North Carolina, USA.^[10]
• 2008-2016 Senior Researcher, Department of Neuroscience and Brain Technologies, Italian Institute of Technology, Genova, Italy.
• 2013-2018 Professor, Skolkovo Institute of Science and Technology^[11]
• Since 2015 Director of Institute of Translational Biomedicine and Head of Laboratory of Neuroscience and Molecular Pharmacology, Saint Petersburg State University.^[12]

Influence

Since 2018 Raul Gainetdinov has been included in the Web of Science Highly Cited Researchers list.^{[13] [14]} h-index 82.^[15]

Since 2013 he has been the chairman of the nomenclature committee for dopamine receptors of International Union of Basic and Clinical Pharmacology (IUPHAR).^[16]

External links

PubMed search for Raul R. Gainetdinov

Notes and References

1. Beaulieu JM, Gainetdinov RR. 2011-03-01. The Physiology, Signaling, and Pharmacology of Dopamine Receptors. Pharmacological Reviews. 63. 1 . 182–217. 10.1124/pr.110.002642. 21303898. 2545878.
2. Beaulieu JM, Sotnikova TD, Marion S, Lefkowitz RJ, Gainetdinov RR, Caron MG. 2005-07-29. An Akt/β-Arrestin 2/PP2A Signaling Complex Mediates Dopaminergic Neurotransmission and Behavior. Cell. 122. 2. 261–273. 10.1016/j.cell.2005.05.012. 16051150. free.
3. Bohn LM, Lefkowitz RJ, Gainetdinov RR, Peppel K, Caron MG, Lin FT. 1999-12-24. Enhanced Morphine Analgesia in Mice Lacking β-Arrestin 2. Science. 286. 5449. 2495–2498. 10.1126/science.286.5449.2495. 10617462.
4. Mohn AR, Gainetdinov RR, Caron MG, Koller BH. 1999-08-20. Mice with Reduced NMDA Receptor Expression Display Behaviors Related to Schizophrenia. Cell. 98. 4. 427–436. 10.1016/S0092-8674(00)81972-8. 10481908. free.
5. 2001-08-14. Following the trace of elusive amines. Proceedings of the National Academy of Sciences. Premont RT, Gainetdinov RR, Caron MG . 98. 17. 9474–9475. 10.1073/pnas.181356198. 11504935. 55475. 2001PNAS...98.9474P. free.
6. 2009-04-23. Trace Amine-Associated Receptors as Emerging Therapeutic Targets. Molecular Pharmacology. Sotnikova TD, Caron MG, Gainetdinov RR . 76. 2. 229–235. 10.1124/mol.109.055970. 19389919. 2713119. free.
7. Gainetdinov RR, Hoener MC, Berry MD. 2018-07-01. Trace Amines and Their Receptors. Pharmacological Reviews. 70. 3. 549–620. 10.1124/pr.117.015305. 29941461. free.
8. Web site: Raul R. Gainetdinov, MD, PhD Parkinson's Disease . 2022-08-09 . www.michaeljfox.org . en.
9. Web site: Dr. Raul R Gainetdinov Insight Medical Publishing. 2021-09-20. www.imedpub.com.
10. Web site: Institute of Translational Biomedicine.
11. Web site: Raul Gainetdinov . 2022-08-12 . ORCID.
12. Web site: Laboratory of Neuroscience and Molecular Pharmacology.
13. Web site: Web of Science Highly Cited Researchers 2019. Web of Science.
14. Web site: Web of Science Highly Cited Researchers 2020. Web of Science.
15. Web site: Raul R. Gainetdinov.
16. Web site: IUPHAR subcommittee and family contributors.